Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 9
2014 10
2015 11
2016 6
2017 5
2018 5
2019 15
2020 18
2021 26
2022 26
2023 15
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Bataller A, et al. Among authors: yilmaz m. Haematologica. 2024 May 2. doi: 10.3324/haematol.2024.285057. Online ahead of print. Haematologica. 2024. PMID: 38695144 Free article.
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
Abuasab T, Borthakur G, Kanagal-Shamanna R, Masarova L, Patel K, Takahashi K, Bose P, Villarreal J, Pierce S, Kadia T, Garcia-Manero G, Short NJ, DiNardo C, Daver N, Ravandi F, Kantarjian H, Verstovsek S, Yilmaz M. Abuasab T, et al. Among authors: yilmaz m. Am J Hematol. 2024 Apr 13. doi: 10.1002/ajh.27333. Online ahead of print. Am J Hematol. 2024. PMID: 38613831 No abstract available.
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Bazinet A, et al. Among authors: yilmaz m. Lancet Haematol. 2024 Apr;11(4):e287-e298. doi: 10.1016/S2352-3026(24)00034-6. Lancet Haematol. 2024. PMID: 38548404 Clinical Trial.
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Bazinet A, et al. Among authors: yilmaz m. Lancet Haematol. 2024 Apr;11(4):e276-e286. doi: 10.1016/S2352-3026(24)00033-4. Epub 2024 Mar 4. Lancet Haematol. 2024. PMID: 38452788 Clinical Trial.
Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
Sasaki K, Ravandi F, Kadia T, DiNardo CD, Yilmaz M, Short N, Jabbour E, Patel KP, Loghavi S, Pierce S, Borthakur G, Kantarjian H. Sasaki K, et al. Among authors: yilmaz m. Clin Lymphoma Myeloma Leuk. 2024 Feb 3:S2152-2650(24)00059-4. doi: 10.1016/j.clml.2024.01.015. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38431521
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Bataller A, et al. Among authors: yilmaz m. Am J Hematol. 2024 Apr;99(4):792-796. doi: 10.1002/ajh.27236. Epub 2024 Feb 15. Am J Hematol. 2024. PMID: 38361282
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Short NJ, et al. Among authors: yilmaz m. J Clin Oncol. 2024 May 1;42(13):1499-1508. doi: 10.1200/JCO.23.01911. Epub 2024 Jan 26. J Clin Oncol. 2024. PMID: 38277619 Clinical Trial.
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Bataller A, et al. Among authors: yilmaz m. Blood Adv. 2024 Feb 27;8(4):927-935. doi: 10.1182/bloodadvances.2023011757. Blood Adv. 2024. PMID: 38113472 Free PMC article.
138 results